KYNB · All filings · Read this filing
What changed 10-Q
Item 5. Other Information
2022-11-07 compared with 2022-08-08 · 4 added, 2 removed, 29 unchanged (17% of the section changed)
7 unchanged sentences
and AstraZeneca AB, dated as of October 20, 2014.
+Added: Equity Distribution Agreement, dated August 8, 2022, among FibroGen, Inc.
+Added: and Goldman Sachs & Co.
Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).
12 unchanged sentences
FibroGen, Inc.
−Removed: August 8, 2022
+Added: November 7, 2022
/s/ Enrique Conterno
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 8, 2022
+Added: November 7, 2022
/s/ Juan Graham
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.